OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
2
Results
Show all
Save search
Copy query
Show results for
Unknown
(2)
Publication Date
Release Date
2025
(2)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
MELK prevents radiofrequency ablation-induced immunogenic cell death and antitumor immune response by stabilizing FABP5 in hepatocellular malignancies.
Not available
S-EPMC11773770
|
biostudies-literature
Cite
Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial.
Not available
S-EPMC11799164
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
